LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression

• DOI: 10.18632/oncotarget.21719
• Publication Date: 2017-10-11T01:14:57Z
• Authors: Yang Du; Xiao-Dong Weng; Lei Wang; Xiu-Heng Liu; Heng-Cheng Zhu; Jia Guo; Jin-Zhuo Ning; Cheng-Cheng Xiao
• Keywords: XIST

Accumulating evidences have indicated that aberrant expression of long non-coding RNAs (LncRNAs) is tightly associated with cancer development. Previous studies reported lncRNA XIST regulates tumor malignancies in several cancers. However, the underlying mechanism prostate remains unclear. In current study, we found was down-regulated specimens and cell lines. Low correlated poor prognosis advanced stage patients. gain loss function assays, confirmed suppressed cellular proliferation metastasis both vitro vivo. Furthermore, negatively miR-23a subsequently promotes RKIP at post-transcriptional level. Consequently, investigated correlation between miR-23a, identified as a direct target XIST. addition, over-expression efficiently abrogated up-regulation induced by XIST, suggesting positively competitively binding to miR-23a. Taken together, our study acts suppressor cancer, this regulatory effect will shed new light on epigenetic diagnostics therapeutics cancer.